Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuncell-LC plus Nivolumab in Advanced Gastric Cancer
NCT05053295Unknown
- Sponsor
- Gangnam Severance Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of immuncell-lc in gastric adenocarcinoma and gastroesophageal junction cancer, sponsored by Gangnam Severance Hospital. Primary endpoint: Objective Response Rate up to 12 months. Status: unknown.
02
Drugs
immuncell-lc
03
Conditions
gastric adenocarcinomagastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05053295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053295.